Evercore HC Menlo vs Lazard HC SF
Curious on how these two groups stack up against one another in terms of deal flow, culture, pay, and overall the better place to work (objectively).
Trending Content - Investment Banking Forum
| +441 | Is UBS really that bad? | 81 | 1d |
| +317 | Which Offer to Accept: UBS Analyst Role or Part Time Cashier at the Local Taco Bell | 37 | 8h |
| +223 | Is Houston SA 28 recruiting already over? | 49 | 4h |
| +158 | FIG Pigeonholes you - is it true? | 25 | 16h |
| +146 | Differences in Restructuring Teams? | 28 | 3h |
| +141 | Roku-Fox Deal - UBS Misses Out on yet another deals after years chasing this deal | 22 | 12h |
| +140 | GF is an IB Analyst at a top BB, hates it, what exit options does she have? | 24 | 8h |
| +135 | TPH V.S. Mizuho [HOU] | 19 | 3h |
| +129 | How do you manage nerves in IB technical interviews? | 12 | 6h |
| +116 | Useless associates | 27 | 14h |
Career Resources
evercore pays more, is much better in terms of dealflow (lowk evercore is top 2 after poaching ben carpenter from JPM) and Laz only had 1 M&A pharma deal in 2025 (and the MD who brought that deal in j left for Leerink M&A), Laz probs has better culture (WFH monday and friday, people are all great). If you are optimizing for a great time pick Laz, if you are optimizing for deal flow, comp, and exits, def go evercore (only better shop is CVP and maybe GS).
Fuck California come to NYC like a real man
If I were in your shoes and had offers from both, I’d take Evercore Menlo over Lazard SF. Not just for the stronger M&A deal flow, but because the Evercore platform in biopharma feels like it has more momentum right now given the mandates they’ve been landing and the overall trajectory of the group with some of the recent hires they've made. You also get the added bonus of getting some capital markets exposure since Evercore’s team is occasionally involved on some impactful IPOs and follow-ons/PIPEs, which I'd argue is important if you possibly want to go down the VC route.
I go more into detail here in case you're interested: [Early 2026] The Definitive and Data-Driven Healthcare IB Group Rankings (Biopharma + Broader HC) | Wall Street Oasis
EVR Menlo HC imo, better platform and trajectory (+ comp too). LAZ HC is not the same as it was
bump
Sit ullam velit assumenda ut. Ratione perspiciatis fugiat quae. Ex suscipit cum voluptates. Veritatis commodi ab sed in dolorum suscipit. Natus excepturi doloribus voluptas consequatur qui eum.
Quae ab placeat dolorum sed. Sed enim aut voluptatum velit maxime eius ut exercitationem. Maxime blanditiis consequuntur mollitia laudantium modi nemo.
Assumenda harum velit expedita pariatur labore. Sed accusamus esse nam unde voluptatibus. Quo minus fugiat dignissimos eos. Ut ex nobis aut culpa labore saepe similique similique. Ea in dolorem saepe voluptas accusamus quo. Quia optio aliquid ipsam repellendus.
Aut vel corporis quidem vel eum aliquid. Inventore ea eum autem nostrum quibusdam. Voluptatem tempore excepturi quibusdam. Amet voluptate molestiae et ea ut. Fugit autem rerum repellendus molestiae ad asperiores.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...